Avita Medical (NASDAQ:RCEL) Shares Up 4.6% – Still a Buy?

Avita Medical Inc. (NASDAQ:RCEL – Get Free Report)’s share price shot up 4.6% on Tuesday. The stock traded as high as $15.84 and last traded at $15.92. 40,973 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 344,605 shares. The stock had previously closed at $15.22.

Analyst Ratings Changes

Several research firms recently issued reports on RCEL. Weiss Ratings reissued a “sell (e+)” rating on shares of Avita Medical in a research note on Monday, September 21st. Lake Street Capital boosted their target price on shares of Avita Medical from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. BTIG Research raised their price objective on shares of Avita Medical from $15.00 to $21.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Wall Street Zen upgraded shares of Avita Medical from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, TD Cowen raised their target price on shares of Avita Medical from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, November 12th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Avita Medical has an average rating of “Moderate Buy” and an average price target of $16.60.

Get Our Latest Stock Analysis on RCEL

Avita Medical Trading Up 2.0%

The firm has a market capitalization of $487.61 million, a PE ratio of -13.17 and a beta of 2.03. The stock’s 50 day moving average price is $13.48 and its two-hundred day moving average price is $7.22.

Avita Medical (NASDAQ:RCEL – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. The company had revenue of $26.11 million during the quarter, compared to analysts’ expectations of $22.35 million. Analysts expect that Avita Medical Inc. will post -0.94 earnings per share for the current year.

Institutional Trading of Avita Medical

Hedge funds have recently added to or reduced their stakes in the business. Cetera Investment Advisers purchased a new stake in Avita Medical in the third quarter valued at approximately $127,000. Harpswell Capital Advisors LLC purchased a new stake in shares of Avita Medical during the third quarter worth about $150,000. China Universal Asset Management Co. Ltd. increased its holdings in Avita Medical by 28.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock worth $191,000 after purchasing an additional 3,500 shares during the last quarter. Quantinno Capital Management LP bought a new stake in shares of Avita Medical in the first quarter worth $83,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Avita Medical in the 2nd quarter valued at about $95,000. 27.66% of the stock is owned by institutional investors and hedge funds.

About Avita Medical

(Get Free Report)

AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient’s healthy skin to prepare a suspension of skin cells for application to wounds. The company’s RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.

Read More

Receive News & Ratings for Avita Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical and related companies with MarketBeat.com's FREE daily email newsletter.